Literature DB >> 6846300

Why do apparently healthy people use antacid tablets?

D Y Graham, J L Smith, D J Patterson.   

Abstract

Proprietary antacids represent a multimillion dollar business in this country. Marketing surveys have shown that approximately one-half of American adults have used antacids. Twenty-seven percent of adults take 2 or more doses per month. Seventy-five percent of total antacid consumption is by heavy users, defined as greater than 6 doses per week (less than 5% of adults). We investigated why apparently healthy people are heavy antacid users. Thirty-seven heavy users were evaluated. The median duration of antacid use was 20 years, and most took antacids 2-6 times per day, concentrated through the work week. The primary diagnosis was reflux esophagitis in 31 (84%), peptic ulcer disease in one, and nonulcer dyspepsia in five. Ninety-five percent had symptoms consistent with reflux esophagitis. Thirty-three completed a 1 month double-blind, randomized cross-over trial of antacid tablets (14 mEq neutralizing capacity per tablet) versus placebo. Twenty-nine correctly identified the antacid product (p less than 0.0001). Twenty-three subjects underwent Bernstein tests and endoscopy; 21 had positive Bernstein tests, 13 had definite esophagitis as determined endoscopically. We conclude 1) heavy proprietary antacid tablet use in the adult male is not an expression of functional disease but is due to reflux esophagitis, 2) tablet use can be effective symptomatic treatment, and 3) history is an adequate evaluation for most heavy antacid tablet users.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6846300

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  18 in total

1.  Role of saliva in esophageal function and disease.

Authors:  J F Helm
Journal:  Dysphagia       Date:  1989       Impact factor: 3.438

Review 2.  Treatment of gastro-oesophageal reflux disease in adults.

Authors:  J P Galmiche; E Letessier; C Scarpignato
Journal:  BMJ       Date:  1998-06-06

3.  Therapeutic efficacy revisited.

Authors:  D Y Graham
Journal:  Dig Dis Sci       Date:  1984-06       Impact factor: 3.199

Review 4.  Epidemiology of gastro-esophageal reflux disease.

Authors:  P J Howard; R C Heading
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

Review 5.  Management of dyspepsia in general practice. A critical assessment.

Authors:  C Tosetti; V Stanghellini
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

6.  Antacid use in a family-practice population.

Authors:  R V Birtwhistle
Journal:  Can Fam Physician       Date:  1988-08       Impact factor: 3.275

7.  Twenty to 40 year follow up of infantile hiatal hernia.

Authors:  B T Johnston; I J Carré; P S Thomas; B J Collins
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

8.  Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients.

Authors:  E Kuster; E Ros; V Toledo-Pimentel; A Pujol; J M Bordas; L Grande; C Pera
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

9.  Comparative study of four antacids.

Authors:  M R Jacyna; E J Boyd; K G Wormsley
Journal:  Postgrad Med J       Date:  1984-09       Impact factor: 2.401

Review 10.  Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.

Authors:  N J Bell; R H Hunt
Journal:  Gut       Date:  1992-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.